Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2017-07-25 Interim / Quarterly Rep…
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Appendix 4C - Quarterly 6 pages 1.5MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly results for the period ended 30 June 2017' and includes detailed financial data such as cash flow statements for the quarter and year to date. It references Appendix 4C, which is a quarterly cash flow report required by the ASX Listing Rules. The content includes actual financial figures and analysis for a period shorter than a full fiscal year, consistent with an interim or quarterly report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q4 2017
2017-07-25 English
US patent allowed for Sygenus for acne 2 pages 110.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Regeneus regarding the United States Patent Office's decision to allow a patent for their Sygenus secretions technology for acne. It discusses patent details, commercial rights, and ongoing preclinical studies. There is no financial data, no report attached or referenced as being published, and no mention of annual or interim financial results. The content is a regulatory announcement about intellectual property and business development, not a financial report or management discussion. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2017-07-09 English
Q2 2017 Update 7 pages 2.0MB
Regulatory Filings Classification · 90% confidence The document contains only placeholders for images and no textual content or financial data. It is extremely short (385 characters) and does not provide any report, announcement, or detailed information. Given the lack of content, it cannot be classified as a substantive report or announcement. It fits best as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings without clear classification.
2017-07-04 English
RGS to receive milestone payment for successful Phase I 1
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Regeneus regarding a milestone payment received for meeting primary endpoints in a clinical trial. It discusses a milestone payment under a licensing agreement and provides background on the companies involved. The document is short (2910 characters) and is an announcement of a specific event related to financing or capital structure (milestone payment under a licensing agreement). It does not contain financial statements or detailed financial results, nor is it a report or transcript. Therefore, it fits best under Capital/Financing Update (CAP).
2017-06-20 English
RGS presentation to ChinaBio Partnering Forum 22 pages 1.4MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about Regeneus Ltd, focusing on its technology platforms, product pipelines, clinical trial updates, collaborations, and development milestones. It contains forward-looking statements, product descriptions, clinical trial results, and strategic partnership information. The content is structured as a presentation with slides and images (omitted here), typical of investor or corporate presentations. There is no indication that this is a formal regulatory filing, audit report, earnings release, or annual/interim report. The document is not a transcript of a call, nor a voting result or director dealing report. It is clearly a comprehensive investor presentation aimed at informing stakeholders about the company's technology, clinical progress, and strategic direction. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2017-05-30 English
Japanese Patent Office to grant key patent for Progenza 2 pages 112.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 24 May 2017 regarding the Japanese Patent Office decision to grant a key patent for Regeneus' Progenza stem cell technology. It discusses patent details, licensing, and the company's technology platform. There are no financial statements, earnings data, or detailed management analysis. The document is a corporate announcement about intellectual property and business development, not a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The content fits best under a general regulatory announcement category. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2017-05-23 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.